Napredna pretraga

Pregled bibliografske jedinice broj: 668707

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma


Hudolin, Tvrtko; Kaštelan, Željko; Ilić, Ivana; Levarda-Hudolin, Katarina; Bašić-Jukić, Nikolina; Rieken, M.; Spagnoli, G.C.; Juretić, Antonio; Mengus, C.
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma // Journal of translational medicine, 11 (2013), 123-1 doi:10.1186/1479-5876-11-123 (međunarodna recenzija, članak, znanstveni)


Naslov
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma

Autori
Hudolin, Tvrtko ; Kaštelan, Željko ; Ilić, Ivana ; Levarda-Hudolin, Katarina ; Bašić-Jukić, Nikolina ; Rieken, M. ; Spagnoli, G.C. ; Juretić, Antonio ; Mengus, C.

Izvornik
Journal of translational medicine (1479-5876) 11 (2013); 123-1

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Primary testicular lymphoma; DLBCL; cancer/testis antigens; MAGE-A; NY-ESO-1; immunotherapy

Sažetak
Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the development of novel forms of therapy is urgently required. Specific immunotherapy generating immune responses directed against antigen predominantly expressed by cancer cells such as cancer-testis antigens (CTA) may provide a valid alternative treatment for patients bearing PTL, alone or in combination with current therapies. Three monoclonal antibodies (mAbs), 77B recognizing MAGE-A1, 57B recognizing an epitope shared by multiple MAGE-A CTA (multi-MAGE-A specific) and D8.38 recognizing NY-ESO-1/LAGE-1 were used for immunohistochemical staining of 27 PTL, including 24 DLBCL. RESULTS: Expression of MAGE-A1 was infrequently detectable in DLBCL specimens (12.50%), whereas multi-MAGE-A and NY-ESO-1/LAGE-1 specific reagents stained the cytoplasms of tumor cells in DLBCL specimens with higher frequencies (54.17% and 37.50%, respectively) with different expression levels. These results suggest that MAGE-A and NY-ESO- 1/LAGE-1, possibly in combination with other CTA, might be used as targets for specific immunotherapy in DLBCL.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1080134-0122 - Čimbenici rizika za razvoj ateroskleroze nakon transplantacije bubrega (Nikolina Bašić-Jukić, )
214-0000000-3601 - Učinak zračenja u bolesnika s rakom prostate na Tregs-limfocite (Antonio Juretić, )

Ustanove
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati